adagrasib
mirati
['krystal 1', 'adagrasib']
krystal 1 trial simultaneous presentation at asco 2022 and publication in the nejm. we now have a new inhibitor for kras g12c. adagrasib, a krasg12c inhibitor, irreversibly and selectively binds krasg12c, locking it in its inactive state. + 
A dedicated conference for oncology held under the theme "Access. Educate. Collaborate"